OPKO Health, Inc. (TLV:OPK)
435.90
-3.10 (-0.71%)
Nov 6, 2025, 5:29 PM IDT
OPKO Health Revenue
OPKO Health had revenue of $151.67M USD in the quarter ending September 30, 2025, a decrease of -12.65%. This brings the company's revenue in the last twelve months to $642.07M, down -9.75% year-over-year. In the year 2024, OPKO Health had annual revenue of $713.14M, down -17.41%.
Revenue (ttm)
$642.07M
Revenue Growth
-9.75%
P/S Ratio
1.58
Revenue / Employee
$214.24K
Employees
2,997
Market Cap
3.36B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 713.14M | -150.35M | -17.41% |
| Dec 31, 2023 | 863.50M | -140.70M | -14.01% |
| Dec 31, 2022 | 1.00B | -770.52M | -43.42% |
| Dec 31, 2021 | 1.77B | 339.31M | 23.64% |
| Dec 31, 2020 | 1.44B | 533.48M | 59.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.84B |
| Novolog (Pharm-Up 1966) | 2.04B |
| Ilex Medical | 927.57M |
| Kamada | 571.15M |
| SofWave Medical | 255.13M |
| InterCure | 243.12M |
| BrainsWay | 155.27M |
OPKO Health News
- 9 days ago - OPKO Health Inc (OPK) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Performance - GuruFocus
- 9 days ago - Q3 2025 OPKO Health Inc Earnings Call Transcript - GuruFocus
- 9 days ago - OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands - Nasdaq
- 10 days ago - OPK: Barrington Research Maintains Outperform Rating with $2.25 Price Target | OPK Stock News - GuruFocus
- 10 days ago - Decoding OPKO Health Inc (OPK): A Strategic SWOT Insight - GuruFocus
- 10 days ago - OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics - Nasdaq
- 10 days ago - OPK Reports Decline in Q3 Revenue but Sees Boost in Operating Income - GuruFocus